Is Dynavax Technologies Stock a Buy?
Dynavax Technologies (NASDAQ: DVAX) is a small-cap, early commercial-stage biotech with a lot of promise. The company's hepatitis B vaccine Heplisav-B can be dosed less frequently than the current cohort of standard-bearers, which should lead to significantly higher compliance rates.
What's more, it also confers superior immunogenicity when pitted against other well-established hepatitis B vaccines like GlaxoSmithKline's Engerix-B. Dynavax believes that Heplisav-B can eventually achieve peak sales in the U.S. of around $500 million. That's quite a payday for a company with a market cap of about $430 million right now.
Despite the attractive value proposition, however, Dynavax's shares have slid by 10.5% since the start of 2020. In total, the biotech's stock has now lost a staggering 54% of its value over just the prior 12 months. Should bargain hunters pounce on this beaten-down biotech stock, or is it best to stick to the safety of the sidelines? Let's dig deeper to find out.
Source Fool.com
